Genexine. has filed a patent for a pharmaceutical composition containing an IL-7 fusion protein with an immunoglobulin Fc region. This composition aims to induce a robust immune response when administered, potentially preventing or treating diseases caused by human papillomavirus. GlobalData’s report on Genexine gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Genexine Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genexine, Peptide pharmacophores was a key innovation area identified from patents. Genexine's grant share as of January 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical composition for preventing or treating hpv-caused diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Genexine Inc

A pharmaceutical composition patent (Publication Number: US20240018205A1) discloses a novel interleukin-7 (IL-7) fusion protein comprising an IL-7 protein and an immunoglobulin Fc region. The IL-7 protein can be conjugated to the N-terminus or C-terminus of the Fc region and may include an oligopeptide of 1 to 10 amino acid residues. The composition specifies that the IL-7 protein should have at least 70% sequence identity to specific amino acid sequences. Additionally, the Fc region includes specific CH2 and CH3 domains derived from human IgD and IgG4, with variations in amino acid sequences outlined in the patent.

Furthermore, the patent claims methods for preventing or treating genital diseases using the IL-7 fusion protein and a pharmaceutically acceptable carrier. It also describes a method for increasing immune response in mucosal tissues by administering the pharmaceutical composition. The patent extends to modified IL-7 fusion proteins that lack a signal peptide and include specific amino acid sequences. Methods for producing these modified proteins involve transforming cells with nucleic acid sequences encoding the IL-7 protein and Fc region, with an emphasis on codon optimization for efficient production. Overall, the patent outlines the development and application of IL-7 fusion proteins for therapeutic purposes, highlighting their potential in treating various diseases and enhancing immune responses in specific tissues.

To know more about GlobalData’s detailed insights on Genexine, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies